Indre Ceponiene: Major Gaps in Secondary Cardiovascular Prevention Across Europe
Indre Ceponiene, Head of Cardiovascular CT Department at The Hospital of Lithuanian University of Health Sciences Kauno klinikos, shared a post on LinkedIn:
“As a national investigator, I am proud to share the primary results of the EUROASPIRE VI survey presented at the ESC Congress 2026.
The study included 8,590 patients across 27 countries, evaluated a median of 13.2 months after an index cardiovascular event.
It showed profound variation in how well secondary prevention targets are achieved between countries.
Across the cohort, the residual risk burden remained unacceptably high:
- 83percent had LDL C above 1.4 mmol/L
- 60percent had blood pressure above 130/80 mmHg
- 31percent had chronic kidney disease
These findings echo international evidence that lipid and blood pressure targets are frequently not attained after coronary hospitalisation.
For Lithuania, the results are cautiously encouraging and definitely a step forward.
Our 14percent guideline target score places us closer to the international middle and represents the one of the best performances among the participating high risk countries.
Nevertheless, this also means that many patients remain above recommended lipid and blood-pressure targets after a coronary event an important call to further strengthen long term, guideline directed care.
One particularly positive finding is cardiac rehabilitation: 78percent of Lithuanian patients attended rehabilitation, the second highest result among participating countries.
This is an important national strength that should be protected, sustained and further developed.
Participation in cardiac rehabilitation was associated with:
- Better blood pressure control
- Better LDL C and HbA1c target attainment
- Better kidney function
- Significantly greater use of antiplatelets, lipid lowering therapies and beta blockers.
Thanks to our Lithuanian University of Health Sciences Heart Centre Team for devoting their time and effort to participate in this important registry.”
Stay updated with Hemostasis Today.
-
Oct 21, 2026, 16:57Fabrice Cognasse: Celebrating the Next Generation of Platelet Research and Transfusion Medicine
-
Oct 21, 2026, 16:47Christabel Odeta: Treating Pediatric Cancer in Children With Sickle Cell Disease
-
Oct 21, 2026, 16:36Sharlene Haywood: Bringing Multidisciplinary Learning Into Nursing Practice
-
Oct 21, 2026, 16:19Vanessa Carvalho: New Research on Platelet-Derived Extracellular Vesicles in Preeclampsia
-
Oct 21, 2026, 15:41Women and Hemostasis Across Hormonal Transition
-
Oct 21, 2026, 15:35Danny Hsu: Pharma’s 2025 Blockbusters Through a Hematologist’s Lens
-
Oct 21, 2026, 15:12Yue Zhang: Flow Cytometry for Translational Immunology and Cancer Research
-
Oct 21, 2026, 14:58Radoš Stefanović: How Red Blood Cells Adapt After Exercise
-
Oct 21, 2026, 14:08Vera Ghali: The Role of Hepcidin Assays in Diagnosing Iron Disorders